Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease
Identifieur interne : 000F65 ( Main/Corpus ); précédent : 000F64; suivant : 000F66Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease
Auteurs : Ray L. Watts ; Kelly E. Lyons ; Rajesh Pahwa ; Kapil Sethi ; Matthew Stern ; Robert A. Hauser ; Warren Olanow ; Alex M. Gray ; Bryan Adams ; Nancy L. EarlSource :
- Movement Disorders [ 0885-3185 ] ; 2010-05-15.
English descriptors
Abstract
Levodopa‐induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once‐daily ropinirole 24‐hour prolonged‐release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged‐release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged‐release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22890
Links to Exploration step
ISTEX:AE8F7B691828FAC84E10FA533BFBF8E6336E99D6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title><author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name><affiliation><mods:affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA</mods:affiliation></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</mods:affiliation></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</mods:affiliation></affiliation></author><author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name><affiliation><mods:affiliation>Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Gray, Alex M" sort="Gray, Alex M" uniqKey="Gray A" first="Alex M." last="Gray">Alex M. Gray</name><affiliation><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Adams, Bryan" sort="Adams, Bryan" uniqKey="Adams B" first="Bryan" last="Adams">Bryan Adams</name><affiliation><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name><affiliation><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AE8F7B691828FAC84E10FA533BFBF8E6336E99D6</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22890</idno><idno type="url">https://api.istex.fr/document/AE8F7B691828FAC84E10FA533BFBF8E6336E99D6/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000F65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title><author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name><affiliation><mods:affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA</mods:affiliation></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</mods:affiliation></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</mods:affiliation></affiliation></author><author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name><affiliation><mods:affiliation>Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, Mount Sinai Medical Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Gray, Alex M" sort="Gray, Alex M" uniqKey="Gray A" first="Alex M." last="Gray">Alex M. Gray</name><affiliation><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Adams, Bryan" sort="Adams, Bryan" uniqKey="Adams B" first="Bryan" last="Adams">Bryan Adams</name><affiliation><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name><affiliation><mods:affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05-15">2010-05-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="858">858</biblScope><biblScope unit="page" to="866">866</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">AE8F7B691828FAC84E10FA533BFBF8E6336E99D6</idno><idno type="DOI">10.1002/mds.22890</idno><idno type="ArticleID">MDS22890</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>dyskinesia</term><term>levodopa</term><term>ropinirole prolonged‐release</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa‐induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once‐daily ropinirole 24‐hour prolonged‐release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged‐release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged‐release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ray L. Watts MD</name><affiliations><json:string>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA</json:string></affiliations></json:item><json:item><name>Kelly E. Lyons PhD</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</json:string></affiliations></json:item><json:item><name>Rajesh Pahwa MD</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</json:string></affiliations></json:item><json:item><name>Kapil Sethi MD</name><affiliations><json:string>Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA</json:string></affiliations></json:item><json:item><name>Matthew Stern MD</name><affiliations><json:string>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Robert A. Hauser MD</name><affiliations><json:string>Department of Neurology, University of South Florida, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Warren Olanow MD</name><affiliations><json:string>Department of Neurology, Mount Sinai Medical Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Alex M. Gray PhD</name><affiliations><json:string>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</json:string></affiliations></json:item><json:item><name>Bryan Adams PhD</name><affiliations><json:string>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</json:string></affiliations></json:item><json:item><name>Nancy L. Earl MD</name><affiliations><json:string>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ropinirole prolonged‐release</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item></subject><articleId><json:string>MDS22890</json:string></articleId><language><json:string>eng</json:string></language><abstract>Levodopa‐induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once‐daily ropinirole 24‐hour prolonged‐release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged‐release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P > 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged‐release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>7.148</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1202</abstractCharCount><pdfWordCount>5182</pdfWordCount><pdfCharCount>32769</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>179</abstractWordCount></qualityIndicators><title>Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title><corporate><json:item><name>On Behalf of the 228 Study Investigators</name></json:item></corporate><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>9</total><last>866</last><first>858</first></pages><issn><json:string>0885-3185</json:string></issn><issue>7</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22890</json:string></doi><id>AE8F7B691828FAC84E10FA533BFBF8E6336E99D6</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/AE8F7B691828FAC84E10FA533BFBF8E6336E99D6/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/AE8F7B691828FAC84E10FA533BFBF8E6336E99D6/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/AE8F7B691828FAC84E10FA533BFBF8E6336E99D6/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Drs. Watts, Lyons, Pahwa, Sethi, Stern, Hauser and Olanow have received research grants and/or consulting fees from GlaxoSmithKline. Drs. Gray, Adams and Earl are or were employees of GlaxoSmithKline.</note><note>GlaxoSmithKline Research and Development</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title><author><orgName>On Behalf of the 228 Study Investigators</orgName></author><author><persName><forename type="first">Ray L.</forename><surname>Watts</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, University of Alabama at Birmingham, 1720, 7th Avenue South, Sparks Center Suite 350A1, Birmingham, AL 35294‐0017</p></note><affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA</affiliation></author><author><persName><forename type="first">Kelly E.</forename><surname>Lyons</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</affiliation></author><author><persName><forename type="first">Rajesh</forename><surname>Pahwa</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</affiliation></author><author><persName><forename type="first">Kapil</forename><surname>Sethi</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA</affiliation></author><author><persName><forename type="first">Matthew</forename><surname>Stern</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USA</affiliation></author><author><persName><forename type="first">Robert A.</forename><surname>Hauser</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Warren</forename><surname>Olanow</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Mount Sinai Medical Center, New York, New York, USA</affiliation></author><author><persName><forename type="first">Alex M.</forename><surname>Gray</surname></persName><roleName type="degree">PhD</roleName><note type="biography">Deceased</note><affiliation>Deceased</affiliation><affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</affiliation></author><author><persName><forename type="first">Bryan</forename><surname>Adams</surname></persName><roleName type="degree">PhD</roleName><affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</affiliation></author><author><persName><forename type="first">Nancy L.</forename><surname>Earl</surname></persName><roleName type="degree">MD</roleName><affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="858">858</biblScope><biblScope unit="page" to="866">866</biblScope></imprint></monogr><idno type="istex">AE8F7B691828FAC84E10FA533BFBF8E6336E99D6</idno><idno type="DOI">10.1002/mds.22890</idno><idno type="ArticleID">MDS22890</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Levodopa‐induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once‐daily ropinirole 24‐hour prolonged‐release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged‐release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged‐release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>dyskinesia</term></item><item><term>Parkinson's disease</term></item><item><term>ropinirole prolonged‐release</term></item><item><term>levodopa</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-10-04">Received</change><change when="2009-10-16">Registration</change><change when="2010-05-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/AE8F7B691828FAC84E10FA533BFBF8E6336E99D6/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mds.v25:7</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2010-05-15">15 May 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="70" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22890</doi><idGroup><id type="unit" value="MDS22890"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-10-04"></event><event type="manuscriptRevised" date="2009-10-07"></event><event type="manuscriptAccepted" date="2009-10-16"></event><event type="firstOnline" date="2010-04-13"></event><event type="publishedOnlineFinalForm" date="2010-05-05"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-04-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-08-12"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">858</numbering><numbering type="pageLast">866</numbering></numberingGroup><correspondenceTo>Department of Neurology, University of Alabama at Birmingham, 1720, 7th Avenue South, Sparks Center Suite 350A1, Birmingham, AL 35294‐0017</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22890.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="25"></count><count type="wordTotal" number="6484"></count></countGroup><titleGroup><title type="main" xml:lang="en">Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Onset of Dyskinesia and Ropinirole Prolonged‐Release</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Ray L.</givenNames><familyName>Watts</familyName><degrees>MD</degrees></personName><contactDetails><email>rlwatts@uab.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Kelly E.</givenNames><familyName>Lyons</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Rajesh</givenNames><familyName>Pahwa</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Kapil</givenNames><familyName>Sethi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Matthew</givenNames><familyName>Stern</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Warren</givenNames><familyName>Olanow</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af7" noteRef="#fn2"><personName><givenNames>Alex M.</givenNames><familyName>Gray</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Bryan</givenNames><familyName>Adams</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Nancy L.</givenNames><familyName>Earl</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author"><groupName>On Behalf of the 228 Study Investigators</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mount Sinai Medical Center, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">dyskinesia</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">ropinirole prolonged‐release</keyword><keyword xml:id="kwd4">levodopa</keyword></keywordGroup><fundingInfo><fundingAgency>GlaxoSmithKline Research and Development</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Levodopa‐induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once‐daily ropinirole 24‐hour prolonged‐release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged‐release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (<i>P</i> < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged‐release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Drs. Watts, Lyons, Pahwa, Sethi, Stern, Hauser and Olanow have received research grants and/or consulting fees from GlaxoSmithKline. Drs. Gray, Adams and Earl are or were employees of GlaxoSmithKline.</p></note><note xml:id="fn2"><p>Deceased</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Onset of Dyskinesia and Ropinirole Prolonged‐Release</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Ray L.</namePart><namePart type="family">Watts</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA</affiliation><description>Correspondence: Department of Neurology, University of Alabama at Birmingham, 1720, 7th Avenue South, Sparks Center Suite 350A1, Birmingham, AL 35294‐0017</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kelly E.</namePart><namePart type="family">Lyons</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rajesh</namePart><namePart type="family">Pahwa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kapil</namePart><namePart type="family">Sethi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical College of Georgia, Augusta, Georgia, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Matthew</namePart><namePart type="family">Stern</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of South Florida, Tampa, Florida, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Warren</namePart><namePart type="family">Olanow</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Mount Sinai Medical Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alex M.</namePart><namePart type="family">Gray</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</affiliation><description>Deceased</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bryan</namePart><namePart type="family">Adams</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nancy L.</namePart><namePart type="family">Earl</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>On Behalf of the 228 Study Investigators</namePart><description>Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USADepartment of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USADepartment of Neurology, Medical College of Georgia, Augusta, Georgia, USADepartment of Neurology, University of Pennsylvania/Pennsylvania Hospital, Philadelphia, Pennsylvania, USADepartment of Neurology, University of South Florida, Tampa, Florida, USADepartment of Neurology, Mount Sinai Medical Center, New York, New York, USADivision of Neurosciences, US Clinical, GlaxoSmithKline, Research Triangle Park, North Carolina, USA</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-05-15</dateIssued><dateCaptured encoding="w3cdtf">2008-10-04</dateCaptured><dateValid encoding="w3cdtf">2009-10-16</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="references">25</extent><extent unit="words">6484</extent></physicalDescription><abstract lang="en">Levodopa‐induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once‐daily ropinirole 24‐hour prolonged‐release (n = 104) in PD patients not optimally controlled with levodopa after up to 3 years of therapy with less than 600 mg/d delays the onset of dyskinesia compared with increasing doses of levodopa (n = 104). During the study, 3% of the ropinirole prolonged‐release group (mean dose 10 mg/d) and 17% of the levodopa group (mean additional dose 284 mg/d) developed dyskinesia (P < 0.001). There were no significant differences in change in Unified Parkinson's Disease Rating Scale activities of daily living or motor scores, suggesting comparable efficacy between the two treatments. Adverse events were comparable in the two groups with nausea, dizziness, insomnia, back pain, arthralgia, somnolence, fatigue, and pain most commonly reported. Ropinirole prolonged‐release delayed the onset of dyskinesia with comparable efficacy to increased doses of levodopa in early PD patients not optimally controlled with levodopa. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Drs. Watts, Lyons, Pahwa, Sethi, Stern, Hauser and Olanow have received research grants and/or consulting fees from GlaxoSmithKline. Drs. Gray, Adams and Earl are or were employees of GlaxoSmithKline.</note><note type="funding">GlaxoSmithKline Research and Development</note><subject lang="en"><genre>Keywords</genre><topic>dyskinesia</topic><topic>Parkinson's disease</topic><topic>ropinirole prolonged‐release</topic><topic>levodopa</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>858</start><end>866</end><total>9</total></extent></part></relatedItem><identifier type="istex">AE8F7B691828FAC84E10FA533BFBF8E6336E99D6</identifier><identifier type="DOI">10.1002/mds.22890</identifier><identifier type="ArticleID">MDS22890</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000F65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:AE8F7B691828FAC84E10FA533BFBF8E6336E99D6
|texte= Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |